Aclarion announced a registered direct offering of 3,380,276 common shares priced at $0.142 per share on January 3, 2025, expecting to raise gross proceeds of approximately $480,000. The offering is scheduled to close around January 6, 2025, subject to customary closing conditions. Dawson James Securities, Inc. serves as the exclusive placement agent, receiving a 7% cash fee of the gross proceeds.The company plans to utilize the net proceeds to fund market development, clinical evidence, product development and quality initiatives, general administration support, and other corporate purposes. The offering is being conducted under an effective S-3 registration statement previously filed with the SEC on September 9, 2024, and declared effective on September 23, 2024.

Aclarion announced a registered direct offering of 3,380,276 common shares priced at $0.142 per share on January 3, 2025, expecting to raise gross proceeds of approximately $480,000. The offering is scheduled to close around January 6, 2025, subject to customary closing conditions. Dawson James Securities, Inc. serves as the exclusive placement agent, receiving a 7% cash fee of the gross proceeds.The company plans to utilize the net proceeds to fund market development, clinical evidence, product development and quality initiatives, general administration support, and other corporate purposes. The offering is being conducted under an effective S-3 registration statement previously filed with the SEC on September 9, 2024, and declared effective on September 23, 2024.